Evidence map›Paper›PMID 39416076›Full record

ArticlebioRxiv : the preprint server for biology2025

Identification of targetable epigenetic vulnerabilities for uveal melanoma.

G Yenisehirli, S Borges, S Braun, A N Zuniga, G I Quintana, J N Kutsnetsoff, S Rodriguez, E V Adis, S Lopez, J J Dollar and 8 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

G YenisehirliDepartment of Ophthalmology and Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine.ORCID 0000-0001-6341-0507
S BorgesDepartment of Ophthalmology and Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine.
S BraunDepartment of Ophthalmology and Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine.
A N ZunigaDepartment of Ophthalmology and Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine.ORCID 0000-0003-0321-674X
G I QuintanaDepartment of Ophthalmology and Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine.
J N KutsnetsoffDepartment of Ophthalmology and Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine.
S RodriguezDepartment of Ophthalmology and Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine.
E V AdisDepartment of Ophthalmology and Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine.ORCID 0000-0003-0606-7604
S LopezDepartment of Ophthalmology and Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine.
J J DollarDepartment of Ophthalmology and Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine.ORCID 0000-0003-2416-4272
V StathiasDepartment of Ophthalmology and Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine.ORCID 0000-0003-1986-5947
C H VolmarCenter for Therapeutic Innovation, University of Miami Miller School of Medicine.ORCID 0000-0001-9437-051X
E KaracaDepartment of Ophthalmology and Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine.ORCID 0000-0003-4109-6013
S P BrothersCenter for Therapeutic Innovation, University of Miami Miller School of Medicine.ORCID 0000-0003-2184-4037
D C BilbaoDepartment of Ophthalmology and Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine.ORCID 0000-0003-1630-8811
J W HarbourDepartment of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, TX.ORCID 0000-0003-0500-0803
Z M CorreaDepartment of Ophthalmology and Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine.ORCID 0000-0003-2946-3757
S KurtenbachDepartment of Ophthalmology and Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine.ORCID 0000-0002-7445-596X

Funding

UT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Kathryn Ann O'Donnell · 2010 to 2026
$53.7M
Tumor Biology Research ProgramP30CA240139 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Stephen D. Nimer · 2019 to 2026
$24.1M
Shared Equipment ModuleP30EY014801 · NEI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Victor L Perez · 2004 to 2026
$12.2M
Stem Cell, Organoid and Cell Phenotyping ModuleP30EY030413 · NEI · UT SOUTHWESTERN MEDICAL CENTER · PI W MATTHEW PETROLL · 2019 to 2026
$5.9M
Developing a high-throughput panel for rapid detection of pathogens causing infectious keratitisR21EY036185 · NEI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI KURTENBACH, STEFAN · 2024 to 2025
$422k
NCI NIH HHS P30 CA142543NCI NIH HHS P30 CA240139NEI NIH HHS P30 EY014801NEI NIH HHS P30 EY030413NEI NIH HHS R21 EY036185
6 · The paper itself

Abstract

Uveal melanoma (UM) is the most common primary intraocular malignancy in adults, with a strong predilection for hepatic metastasis, occurring in approximately 50% of cases. Metastatic UM remains highly resistant to therapy and is almost invariably fatal. The strongest genetic drivers of UM metastasis are loss-of-function mutations in tumor suppressor

Identifiers

PMID39416076
PMCPMC11482939

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.